Qure.ai Aira Receives Class IIb CE Certification for Clinical Decision Support

Qure.ai says its Aira clinical decision support system has received Class IIb CE certification under the European Union Medical Device Regulation. The milestone supports marketing for the certified intended use in applicable European markets. It does not equal FDA authorization, prove better patient outcomes, or remove the need for local clinical and workflow evaluation.

What Qure.ai Aira Is Built to Do

Qure.ai describes Aira as a clinical support layer for frontline primary care. The system combines documentation, workflow automation, electronic patient information, guideline-based recommendations, and follow-up support. The company says it was designed for settings with workforce shortages, limited digitization, local-language needs, and unreliable connectivity.

That scope is wider than a single diagnostic model.

It means buyers need to evaluate several connected functions:

• data capture
• recommendation logic
• user review
• follow-up communication
• system integration
• performance across local guidelines
• patient populations

What Class IIb CE Certification Means for Aira

Class IIb is a higher-risk classification under the EU Medical Device Regulation. Certification indicates that a notified body assessed the device against the applicable regulatory requirements for its stated use. The exact intended purpose, users, clinical context, limitations, and approved documentation still matter.

CE certification is not a general endorsement of every claim a company makes.

It is also not interchangeable with FDA clearance or approval in the United States.

A hospital or ministry should review:

• the certificate
• intended-use language
• instructions
• evidence package
• change controls
• postmarket plan

Early Evidence From Qure.ai Aira Deployments

The company reports:

• ten live pilot sites across Nigeria
• Kenya
• Mozambique
• the Solomon Islands
• Bangladesh

It also reports shorter documentation time and improved completion in selected programs.

These figures come from Qure.ai's announcement, so they should be treated as early company-reported implementation results until methods and independent evidence are available.

The varied settings make localization central to the story. National guidelines, languages, record systems, connectivity, staffing, escalation options, and follow-up resources can all change whether the same system helps.

Aira Procurement Questions for Clinical Teams

• What exact recommendations fall inside the certified intended use?
• Which local guidelines are encoded and who keeps them current?
• Can a health worker inspect the basis for a recommendation?
• How are missing, conflicting, or low-quality patient data handled?
• What happens when connectivity is lost?
• How are disagreements, overrides, and suspected safety events recorded?
• Which performance measures are available by site and patient group?

What to Watch in Aira Deployments

The most useful next evidence will show:

• recommendation quality
• clinical review
• follow-up completion
• subgroup performance
• patient outcomes across different health systems

Scale alone will not answer whether the tool improves decisions safely.

Related Qure.ai and Clinical Decision Support Coverage

• Clinical Decision Support AI
• Qure.ai clinical vendor profile
• Qure.ai lung cancer detection expansion
• How to Evaluate an AI Diagnostic Platform
• FDA and Medical AI Regulation

Reviewed: September 28, 2026. Next review: December 28, 2026.